Literature DB >> 1520017

Haemorrhagic shock encephalopathy syndrome in the British Isles.

C J Bacon1, S M Hall.   

Abstract

The aetiopathogenesis of haemorrhagic shock encephalopathy syndrome (HSES) remains unclear and after concern that a novel environmental agent was the cause, the British Paediatric Association and the Public Health Laboratory Service Communicable Disease Surveillance Centre in 1983 initiated surveillance of this condition in the British Isles. After 1986 cases were ascertained via the British Paediatric Surveillance Unit 'active' reporting scheme; this report presents the findings for 1985-8. Sixty five patients were reported, of whom 52 satisfied the criteria for inclusion. Of those whose outcome was known, 24 (46%) died, 18 had severe neurological damage, and six survived apparently intact. Epidemiological features of note were: the median age of 15 weeks (range 3-140); statistically significant clustering of admission times suggesting a peak onset period at night; lack of geographic clusters, of secular trends and, except for a slight excess in winter months, of seasonality. Clinical and pathological features followed a highly consistent pattern, suggesting that HSES is an individual clinical entity distinguishable from conditions with similar presentations, such as septicaemia and Reye's syndrome. There was no microbiological or epidemiological evidence to support the emergence of a novel environmental agent. Many of the features of HSES were, however, the same as those described in heat stroke and we suggest that the two conditions are the same even though there is usually no history of overt overheating.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1520017      PMCID: PMC1793602          DOI: 10.1136/adc.67.8.985

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  36 in total

1.  The fallacy of the hemorrhagic shock and encephalopathy syndrome.

Authors:  M Bass
Journal:  Am J Dis Child       Date:  1991-07

2.  [Hemorrhagic shock and encephalopathy syndrome in infancy and childhood].

Authors:  M Kirschstein; F Aksu; F Tegtmeyer
Journal:  Monatsschr Kinderheilkd       Date:  1991-02       Impact factor: 0.323

3.  Effects of hyperthermia therapy on the liver. II. Morphological observations.

Authors:  E J Wills; J M Findlay; J P McManus
Journal:  J Clin Pathol       Date:  1976-01       Impact factor: 3.411

4.  The 'H' in hemorrhagic shock and encephalopathy syndrome should be 'hyperpyrexia'.

Authors:  J J Corrigan
Journal:  Am J Dis Child       Date:  1990-10

5.  Hemorrhagic shock and encephalopathy syndrome. Its association with hyperthermia.

Authors:  S Sofer; M Phillip; J Hershkowits; H Bennett
Journal:  Am J Dis Child       Date:  1986-12

6.  Haemorrhagic shock encephalopathy and sudden infant death.

Authors:  J Q Trounce; J Lowe; B W Lloyd; D I Johnston
Journal:  Lancet       Date:  1991-01-26       Impact factor: 79.321

7.  Heat stroke in infancy.

Authors:  W B Wadlington; A L Tucker; F Fly; H L Greene
Journal:  Am J Dis Child       Date:  1976-11

8.  Heatstroke in well-wrapped infants.

Authors:  C Bacon; D Scott; P Jones
Journal:  Lancet       Date:  1979-02-24       Impact factor: 79.321

9.  Haemorrhagic shock encephalopathy.

Authors:  A Y Tam; I O Ng; P T Cheung; T S Tang; C H Li
Journal:  Acta Paediatr Scand       Date:  1989-05

Review 10.  Extreme hyperpyrexia in childhood. Presentation similar to hemorrhagic shock and encephalopathy.

Authors:  W B Caspe; A T Nucci; S Cho
Journal:  Clin Pediatr (Phila)       Date:  1989-02       Impact factor: 1.168

View more
  10 in total

1.  Case control study of thermal environment preceding haemorrhagic shock encephalopathy syndrome.

Authors:  C J Bacon; S A Bell; J M Gaventa; D C Greenwood
Journal:  Arch Dis Child       Date:  1999-08       Impact factor: 3.791

2.  The Swiss Paediatric Surveillance Unit (SPSU).

Authors:  H Zimmermann; D Desgrandchamps; G Schubiger
Journal:  Soz Praventivmed       Date:  1995

3.  Haemorrhagic shock encephalopathy or near miss sudden infant death syndrome?

Authors:  M Samuels; D P Southall
Journal:  Arch Dis Child       Date:  1993-04       Impact factor: 3.791

4.  Continuous infusion of zidovudine in HIV related thrombocytopenia.

Authors:  C Rahimy; E Jacqz-Aigrain; A Broyard; F Brun-Vézinet; E Vilmer
Journal:  Arch Dis Child       Date:  1993-04       Impact factor: 3.791

5.  Possible aetiology of haemorrhagic shock and encephalopathy syndrome in the Negev area of Israel.

Authors:  S Sofer; B Yerushalmi; E Shahak; T Berenstein; H Schulman
Journal:  Arch Dis Child       Date:  1996-10       Impact factor: 3.791

6.  Haemorrhagic shock encephalopathy syndrome presenting with myoglobinuria.

Authors:  N Teig; T G Nuesslein
Journal:  Arch Dis Child       Date:  1996-02       Impact factor: 3.791

7.  Early steroid pulse therapy for children with suspected acute encephalopathy: An observational study.

Authors:  Yusuke Ishida; Masahiro Nishiyama; Hiroshi Yamaguchi; Kazumi Tomioka; Hiroki Takeda; Shoichi Tokumoto; Daisaku Toyoshima; Azusa Maruyama; Yusuke Seino; Kazunori Aoki; Kandai Nozu; Hiroshi Kurosawa; Ryojiro Tanaka; Kazumoto Iijima; Hiroaki Nagase
Journal:  Medicine (Baltimore)       Date:  2021-07-30       Impact factor: 1.817

Review 8.  Influenza-associated neurological complications.

Authors:  Jenny P Tsai; Andrew J Baker
Journal:  Neurocrit Care       Date:  2013-02       Impact factor: 3.210

9.  Successful Outcome in an Adult Patient with Influenza-associated Hemorrhagic Shock and Encephalopathy Syndrome.

Authors:  Yasuhiro Komori; Naohiro Uchida; Naoko Soejima; Yasuhiro Fujita; Hiroyuki Matsumoto
Journal:  Intern Med       Date:  2020-06-09       Impact factor: 1.271

10.  Hemorrhagic shock and encephalopathy syndrome--the markers for an early HSES diagnosis.

Authors:  Hiroshi Rinka; Takeshi Yoshida; Tetsushi Kubota; Miho Tsuruwa; Akihiro Fuke; Akira Yoshimoto; Masanori Kan; Dai Miyazaki; Hideki Arimoto; Toshinori Miyaichi; Arito Kaji; Satoru Miyamoto; Ichiro Kuki; Masashi Shiomi
Journal:  BMC Pediatr       Date:  2008-10-16       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.